Frost & Sullivan Independent Equity Research

Entera Bio developed a delivery platform for replacing injections with pills; the Company has two drugs in clinical phases; market potential for their platform is significant; Entera Bio recently entered into a $270 million license agreement with Amgen; price target is set at $17.6


Company: Entera Bio        

Sector: Healthcare

Report type: Initiation Report

Published on: July 1, 2019